These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26185279)

  • 1. Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.
    Xue S; Posgai A; Wasserfall C; Myhr C; Campbell-Thompson M; Mathews CE; Brusko T; Rabinovitch A; Savinov A; Battaglia M; Schatz D; Haller M; Atkinson MA
    Diabetes; 2015 Nov; 64(11):3873-84. PubMed ID: 26185279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice.
    Suarez-Pinzon WL; Rabinovitch A
    Cell Transplant; 2011; 20(9):1343-9. PubMed ID: 21396168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.
    Parker MJ; Xue S; Alexander JJ; Wasserfall CH; Campbell-Thompson ML; Battaglia M; Gregori S; Mathews CE; Song S; Troutt M; Eisenbeis S; Williams J; Schatz DA; Haller MJ; Atkinson MA
    Diabetes; 2009 Oct; 58(10):2277-84. PubMed ID: 19628781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
    Tian L; Gao J; Hao J; Zhang Y; Yi H; O'Brien TD; Sorenson R; Luo J; Guo Z
    Endocrinology; 2010 Jul; 151(7):3049-60. PubMed ID: 20444936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple drug therapy with GABA, sitagliptin, and omeprazole prevents type 1 diabetes onset and promotes its reversal in non-obese diabetic mice.
    Lagunas-Rangel FA; Koshelev D; Nedorubov A; Kosheleva L; Trukhan V; Rabinovitch A; Schiöth HB; Levit S
    Front Endocrinol (Lausanne); 2022; 13():1028114. PubMed ID: 36339443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
    Haller MJ; Gitelman SE; Gottlieb PA; Michels AW; Perry DJ; Schultz AR; Hulme MA; Shuster JJ; Zou B; Wasserfall CH; Posgai AL; Mathews CE; Brusko TM; Atkinson MA; Schatz DA
    Diabetes; 2016 Dec; 65(12):3765-3775. PubMed ID: 27669730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.
    Cabrera SM; Colvin SC; Tersey SA; Maier B; Nadler JL; Mirmira RG
    Clin Exp Immunol; 2013 Jun; 172(3):375-82. PubMed ID: 23600825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
    Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
    Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.
    Haller MJ; Gitelman SE; Gottlieb PA; Michels AW; Rosenthal SM; Shuster JJ; Zou B; Brusko TM; Hulme MA; Wasserfall CH; Mathews CE; Atkinson MA; Schatz DA
    J Clin Invest; 2015 Jan; 125(1):448-55. PubMed ID: 25500887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoregulatory effect of anti-thymocyte globulin monotherapy on peripheral lymphoid tissues of non-obese diabetic mice.
    Vargova L; Zacharovova K; Dovolilova E; Vojtova L; Saudek F
    Transplant Proc; 2011 Nov; 43(9):3277-80. PubMed ID: 22099776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes.
    Rydén AK; Perdue NR; Pagni PP; Gibson CB; Ratliff SS; Kirk RK; Friesen TJ; Haase C; Coppieters K; von Herrath MG; Boursalian TE
    J Autoimmun; 2017 Nov; 84():65-74. PubMed ID: 28711285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of double negative T cells and anti-thymocyte serum reverses type 1 diabetes in NOD mice.
    Liu T; Cong M; Sun G; Wang P; Tian Y; Shi W; Li X; You H; Zhang D
    J Transl Med; 2016 Feb; 14():57. PubMed ID: 26911290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined intervention for the tertiary prevention of type 1 diabetes.
    Kawasaki E
    J Diabetes Investig; 2016 May; 7(3):300-2. PubMed ID: 27330714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.
    Ding L; Gysemans CA; Stangé G; Heremans Y; Yuchi Y; Takiishi T; Korf H; Chintinne M; Carr RD; Heimberg H; Pipeleers D; Mathieu C
    PLoS One; 2014; 9(9):e107935. PubMed ID: 25268801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.
    Xue S; Wasserfall C; Parker M; McGrail S; McGrail K; Campbell-Thompson M; Schatz DA; Atkinson MA; Haller MJ
    J Diabetes Complications; 2010; 24(3):163-7. PubMed ID: 19217320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.
    Ogawa N; List JF; Habener JF; Maki T
    Diabetes; 2004 Jul; 53(7):1700-5. PubMed ID: 15220193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease.
    Ma H; Lu Y; Li H; Campbell-Thompson M; Parker M; Wasserfall C; Haller M; Brantly M; Schatz D; Atkinson M; Song S
    Diabetologia; 2010 Oct; 53(10):2198-204. PubMed ID: 20593162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice.
    Suarez-Pinzon WL; Cembrowski GS; Rabinovitch A
    Diabetologia; 2009 Aug; 52(8):1680-2. PubMed ID: 19455306
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition.
    Kim DH; Lee JC; Lee MK; Kim KW; Lee MS
    Diabetologia; 2012 Dec; 55(12):3308-17. PubMed ID: 23011352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.
    Alonso N; Julián MT; Carrascal J; Colobran R; Pujol-Autonell I; Rodriguez-Fernández S; Teniente A; Fernández MA; Miñarro A; Ruiz de Villa MC; Vives-Pi M; Puig-Domingo M
    PLoS One; 2015; 10(11):e0142186. PubMed ID: 26555789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.